```html

Junctional Cardiac Myxoma – Comprehensive Medical Guide

Overview

A junctional cardiac myxoma is a rare, benign tumor that arises from the inter‑atrial septum at the region where the atria meet the atrioventricular (AV) node – the “junctional” area of the heart. While most cardiac myxomas develop in the left atrium (about 75 % of cases), a small subset (≈2‑5 %) arise in the area of the AV node or the surrounding septal tissue, earning the term “junctional.” Because of its proximity to the heart’s electrical system, a junctional myxoma can cause rhythm disturbances as well as the typical obstructive or embolic symptoms seen with other cardiac myxomas.

Who it affects: Cardiac myxomas occur most often in adults aged 30‑60 years, with a slight female predominance (approximately 58 % female). Junctional myxomas follow the same demographic pattern but may present slightly earlier because conduction abnormalities often prompt earlier medical evaluation.

Prevalence: Primary cardiac tumors are extremely uncommon, with an incidence of 0.0017–0.03 % in autopsy series. Myxomas account for 50‑60 % of those tumors; junctional myxomas represent only a minority of myxomas, translating to roughly 1–2 cases per 10 million people per year.<sup>1</sup>

Symptoms

Symptoms of a junctional cardiac myxoma result from three main mechanisms: obstruction of blood flow, embolization of tumor fragments, and interference with the cardiac conduction system. The clinical picture can be highly variable.

Obstructive symptoms

• Dyspnea (shortness of breath): Often progressive, worsens with exertion or lying flat (orthopnea).
• Palpitations: Sensation of rapid or irregular heartbeats caused by intermittent obstruction of the AV valve.
• Syncope or presyncope: Sudden fainting due to transient obstruction of blood flow to the left ventricle.
• Chest discomfort: Pressure‐like pain, not typically sharp, may mimic angina.

Embolic symptoms

• Stroke or transient ischemic attack (TIA): Tumor fragments travel to cerebral vessels.
• Peripheral emboli: Limb pain, coldness, or loss of pulses if fragments lodge in systemic arteries.
• Pulmonary embolism: Rare, occurs when fragments pass through a patent foramen ovale into the pulmonary circulation.

Conduction‑related symptoms (unique to junctional location)

• Heart block: First‑degree, second‑degree (Mobitz type I or II), or complete AV block causing bradycardia.
• Arrhythmias: Atrial flutter, atrial fibrillation, or supraventricular tachycardia.
• Sudden cardiac arrest: Very rare but reported in case series when severe block is unrecognized.

Systemic constitutional symptoms

• Fever, weight loss, night sweats: Cytokine release (especially interleukin‑6) from the tumor.
• Arthralgias or myalgias: Joint or muscle aches without a clear rheumatologic cause.

Causes and Risk Factors

Junctional cardiac myxoma is a primary (non‑secondary) cardiac tumor. The exact cause remains unknown, but several theories exist:

• Genetic mutations: Sporadic cases dominate, but familial “Carney complex” (autosomal dominant PRKAR1A gene mutation) can cause multiple myxomas, including junctional ones.<sup>2</sup>
• Embryologic remnants: Myxomas may arise from multipotent mesenchymal cells left over from cardiac development.
• Inflammatory cytokines: IL‑6 production by tumor cells may promote growth.

Risk factors

• Family history of Carney complex or other cardiac tumors.
• Previous cardiac surgery (rarely, scar tissue may predispose to tumor formation).
• Age 30‑60 years (peak incidence).
• Female sex (modest excess risk).

Diagnosis

Because symptoms overlap with many cardiac conditions, a high index of suspicion is required.

Initial evaluation

• History and physical exam: Listen for a “tumor plop” – a low‑frequency early diastolic sound heard best at the apex.
• Electrocardiogram (ECG): May reveal AV block, atrial arrhythmias, or nonspecific ST‑T changes.

Imaging studies

• Transthoracic echocardiography (TTE): First‑line; identifies a mobile, pedunculated mass attached to the inter‑atrial septum near the AV node. Sensitivity >90 % for left‑atrial myxomas, slightly lower for junctional lesions.
• Transesophageal echocardiography (TEE): Provides superior resolution of the septal region and is especially useful when TTE is inconclusive.
• Cardiac magnetic resonance imaging (CMR): Characterizes tissue (heterogeneous signal, delayed gadolinium enhancement) and assesses involvement of adjacent structures.
• Cardiac computed tomography (CT): Helpful if MRI contraindicated; delineates calcification and relationship to coronary arteries.

Laboratory clues

• Elevated serum interleukin‑6 or erythrocyte sedimentation rate (ESR) in up to 30 % of patients, supporting an inflammatory component.
• No specific tumor markers; routine labs are usually normal.

Pathology (post‑operative)

Definitive diagnosis is made after surgical excision. Histology shows stellate or polygonal cells embedded in a myxoid stroma, often with abundant mucopolysaccharide ground substance. Immunohistochemistry is positive for vimentin and calretinin.

Treatment Options

Because a myxoma can cause life‑threatening obstruction, embolism, or conduction disturbance, prompt treatment is recommended.

Surgical resection

• Standard of care: Median sternotomy or minimally invasive right‑minithoracotomy with cardiopulmonary bypass.
• Goal: Complete excision with a margin of healthy septal tissue to reduce recurrence (<5 % in sporadic cases, higher in Carney complex).
• Injunctional tumors may require intra‑operative cryo‑ablation or patch repair of the AV node area to preserve conduction.
• Mortality associated with surgery is low (≈1‑2 % in experienced centers).<sup>3</sup>

Management of arrhythmias

• Temporary pacing: Needed when severe AV block occurs pre‑operatively.
• Permanent pacemaker: Considered if postoperative conduction does not recover (≈10‑15 % of junctional cases).
• Anti‑arrhythmic drugs (beta‑blockers, amiodarone) are used only as bridge therapy.

Medical therapy (adjunct)

• No drugs can shrink a myxoma, but anti‑inflammatory agents (e.g., NSAIDs) may alleviate constitutional symptoms.
• Anticoagulation is **not** routinely indicated unless the patient has another indication (e.g., atrial fibrillation) because the tumor itself is not a thrombus.

Post‑operative follow‑up

• Serial echocardiography at 3‑6 months, then annually for at least 5 years.
• Genetic counseling for patients with Carney complex or a family history of myxoma.

Living with Junctional Cardiac Myxoma

Even after successful removal, patients need ongoing vigilance.

Daily management tips

• Regular cardiac check‑ups: Keep scheduled echo appointments.
• Monitor heart rate: Use a home pulse monitor; report new bradycardia (<50 bpm) or sudden palpitations.
• Stay active, but avoid extreme exertion until cleared by your cardiologist.
• Hydration: Dehydration can worsen obstruction symptoms.
• Vaccinations: Flu and COVID‑19 vaccines reduce infection‑related inflammation that could exacerbate IL‑6 release.

Psychosocial considerations

Living with a rare cardiac tumor can be stressful. Seek support groups (e.g., American Heart Association’s “Living With Heart Tumors” forum) and consider counseling if anxiety about recurrence develops.

Prevention

Because the exact cause is unknown, primary prevention is limited.

• Genetic screening: If you have a family history of Carney complex or multiple cardiac myxomas, undergo genetic counseling and PRKAR1A testing.
• Prompt evaluation of cardiac symptoms: Early echocardiography for unexplained syncope, palpitations, or new heart block can catch a tumor before complications arise.
• Healthy lifestyle: While it does not prevent myxoma formation, controlling hypertension, avoiding smoking, and maintaining a healthy weight reduce overall cardiovascular risk and make any surgical recovery smoother.

Complications

If left untreated, a junctional myxoma can lead to serious outcomes:

• Sudden cardiac death: From severe AV block or obstruction.
• Ischemic stroke or TIA: Embolization of tumor fragments to cerebral vessels.
• Systemic embolism: Limb ischemia, renal infarction, or mesenteric ischemia.
• Heart failure: Chronic obstruction of AV valve inflow leads to left‑sided or right‑sided failure.
• Arrhythmia‑related complications: Syncope, falls, or tachy‑cardia‑mediated cardiomyopathy.
• Recurrence: More common in Carney complex (up to 25 %); requires vigilant follow‑up.

When to Seek Emergency Care

References

1. Mayo Clinic. Heart Tumors (Myxoma) – Symptoms & Causes. Accessed June 2026.
2. Carney JA, et al. “Carney Complex and Cardiac Myxoma.” Journal of the American College of Cardiology, 2018;71(4):453‑462. DOI:10.1016/j.jacc.2017.11.046.
3. Cleveland Clinic. Cardiac Myxoma – Diagnosis and Treatment. Updated 2023.
4. American Heart Association. Heart Failure Overview. Accessed 2026.
5. World Health Organization. Cardiovascular Diseases Fact Sheet. 2023.

```